Previous Close | 9.63 |
1-Year Change | -51.61% |
6-Months Change | -37.75% |
3-Months Change | -17.41% |
Moving Avg (50d) | 10.3668 |
Moving Avg (200d) | 14.2763 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 423.2K |
Beta (3-Years) | 1.32 |
Revenue Growth (ttm) | -79.3% |
Net Profit Margin (ttm) | -262.18% |
Return On Assets (ttm) | -41.11% |
EPS (ttm) | -4599.15 |
PE Ratio (ttm) | - |
Dividend Yield | % |
Asset Description: | REGENXBIO Inc. |
Predicted Direction: | Sell |
Signal Strength: | Neutral |
Forecast Date: | 2024-11-12 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
9.782 | 10.07 | 10.261 | 10.549 | 11.029 | 11.508 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |